Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis

  • Anahid Safari Stem Cells Technology Research Center, Shiraz University of Medical Sciences Shiraz, Iran
  • Afshin Borhani-Haghighi Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mehdi Dianatpour Stem Cells Technology Research Center, Shiraz University of Medical Sciences Shiraz, Iran
  • Seyed Taghi Heydari Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
  • Farzaneh Foroughinia 1. Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2. Clinical Pharmacy Department, Shiraz University of Medical Sciences, Shiraz, Iran
  • Gholamhossein Ranjbar Omrani Endocrinology & Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Keywords: Osteoporosis, Postmenopausal, Vitamin D, C-Reactive Protein, Serum Amyloid A Protein, Bone Density


Background: Both vitamin D and inflammation were investigated as important players in the pathogenesis of postmenopausal osteoporosis. This study compared vitamin D, inflammatory the biomarkers serum levels and their association with bone mineral density (BMD) in case and control groups to evaluate the possible immune-regulatory effect of vitamin D in this population. Materials and Methods: Participants in post-menopausal age, were categorized to 44 osteoporotic vs. 44 healthy aged-matched women according to WHO criteria. Total BMD, T- scores, Z-scores as well as fracture risk were measured in both groups, using Hologic system Dual-energy X-ray absorptiometry (DEXA). Serum 25-OH vitamin D, high sensitive CRP (hs-CRP) and serum amyloid A (SAA) were compared between groups. The association between serum biomarkers level and BMD were also investigated. The same evaluations were performed for vitamin D deficient (<20 ng/mL) and non-deficient (≥20 ng/mL) subgroups. Results: Vitamin D deficiency was higher in the osteoporotic group (32.6%) in comparison with the control group (25.6%), but the differences were not significant (P=0.47). There were no significant differences in serum levels of hs-CRP and SAA (P=0.83 and P=0.39) as well. No significant association between serum inflammatory biomarkers, vitamin D, and BMD were detected (P≥0.05). The results were the same for vitamin D deficient and non-deficient subgroups (P≥0.05). Conclusion: In the current study, the beneficial effects of vitamin D as a result of its immune-regulatory mechanisms was not reached. Larger scale studies might pave the way to define vitamin D benefits in postmenopausal osteoporosis. [GMJ.2019;8:e1548]

Author Biography

Anahid Safari, Stem Cells Technology Research Center, Shiraz University of Medical Sciences Shiraz, Iran
Assistant Professor at Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran


Prasad S, Sharma B. Evaluation of role of vitamin-D levels in osteoporosis. Int J Adv Med. 2017; 4(3):701-6.

G R, Gupta A. Vitamin D deficiency in India: prevalence, causalities and interventions. Nutrients. 2014; 6(2):729-75.

PMid:24566435 PMCid:PMC3942730

van Schoor NM, Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):671-80.


Lips P, Hosking D, Lippuner K, Norquist J, Wehren L, Maalouf G, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006; 260(3):245-54.


Heaney RP. Nutritional factors in osteoporosis. Annu Rev Nutr. 1993; 13(1):287-316.


Sadat-Ali M, Al Elq AH, Al-Turki HA, Al-Mulhim FA, Al-Ali AK. Influence of vitamin D levels on bone mineral density and osteoporosis. Ann Saudi Med. 2011; 31(6):602.

PMid:22048506 PMCid:PMC3221132

Christodoulou S, Goula T, Ververidis A, Drosos G. Vitamin D and bone disease. Biomed Res Int. 2013; 2013.

PMid:23509720 PMCid:PMC3591184

Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004; 116 (9):634-9.


Adami S, Bertoldo F, Braga V, Fracassi E, Gatti D, Gandolini G, et al. 25-hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone. 2009;45(3):423-6.


Hosseinpanah F, Rambod M, Hossein-nejad A, Larijani B, Azizi F. Association between vitamin D and bone mineral density in Iranian postmenopausal women. . J Bone Miner Metab. 2008; 26(1):86-92.


Tsai K, Hsu S, Cheng J, Yang R. Vitamin D stores of urban women in Taipei: effect on bone density and bone turnover, and seasonal variation. Bone. 1997; 20(4):371-4.

Sigurdsson G, Franzson L, Steingrimsdottir L, Sigvaldason H. The association between parathyroid hormone, vitamin D and bone mineral density in 70-year-old Icelandic women. Osteoporos Int. 2000; 11(12):1031-5.


Sponholtz TR, Zhang X, Fontes JDT, Meigs JB, Cupples LA, Kiel DP, et al. Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women. Arthritis Care Res. 2014; 66(8):1233-40.

PMid:24375982 PMCid:PMC4069198

de Pablo P, Cooper MS, Buckley CD. Association between bone mineral density and C-reactive protein in a large population-based sample. Arthritis Rheum. 2012; 64(8):2624-31.


Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int. 2005; 16(10):1263-71.


Ganesan K, Teklehaimanot S, Tran T-H, Asuncion M, Norris K. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc. 2005; 97(3):329-33.

Berglundh S, Malmgren L, Luthman H, McGuigan F, Åkesson K. C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporos Int. 2015; 26(2):727-35.


Huang JV, Schooling CM. Inflammation and bone mineral density: A Mendelian randomization study. Sci Rep. 2017; 7(1):8666.

PMid:28819125 PMCid:PMC5561220

Wang Q, Zhu Z, Liu Y, Tu X, He J. Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients. Brain Behav. 2018; 8(2):e00885-e.

PMid:29484258 PMCid:PMC5822590

Arnson Y, Itzhaky D, Mosseri M, Barak V, Tzur B, Agmon-Levin N, et al. Vitamin D inflammatory cytokines and coronary events: a comprehensive review. Clin Rev Allergy Immunol. 2013; 45(2):236-47.


Riasnyĭ VM, Apukhovs'ka LI, Velykyĭ MM, Shymans'kyĭ IO, Labudzyns'kyĭ DO, Komisarenko SV. Immunomodulatory effects of vitamin D3 and bisphosphonates in nutritional osteoporosis in rats. Ukr Biokhim Zh. (1999) 2012; 84(2):73-80.

Iseme RA, McEvoy M, Kelly B, Agnew L, Walker FR, Attia J. Is osteoporosis an autoimmune mediated disorder? Bone Rep. 2017; 7:121-31.

PMid:29124082 PMCid:PMC5671387

Perez-Lopez FR, Brincat M, Erel CT, Tremollieres F, Gambacciani M, Lambrinoudaki I, et al. EMAS position statement: Vitamin D and postmenopausal health. Maturitas. 2012; 71(1):83-8.


Kamath DY, Xavier D, Sigamani A, Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: an Indian perspective. Indian J Med Res. 2015; 142(3):261.

PMid:26458341 PMCid:PMC4669860

Thaler R, Sturmlechner I, Spitzer S, Riester SM, Rumpler M, Zwerina J, et al. Acute-phase protein serum amyloid A3 is a novel paracrine coupling factor that controls bone homeostasis. FASEB J. 2014; 29(4):1344-59.

PMid:25491310 PMCid:PMC4396610

Feng Z-P, Li X-Y, Jiang R, Deng H-C, Yang M, Zhou Q, et al. Associations of SAA1 gene polymorphism with Lipid lelvels and osteoporosis in Chinese women. Lipids Health Dis. 2013; 1 2 (1):39.

PMid:23522429 PMCid:PMC3702468

Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285(6):785-95.


Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013; 40 (1):195-211.

PMid:23402469 PMCid:PMC3572442

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-71.


Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014; 37:S81-S90.


Briot K, Audran M, Cortet B, Fardellone P, Marcelli C, Orcel P, et al. Vitamin D: skeletal and extra skeletal effects; recommendations for good practice. Presse Med. 2009; 38(1):43-54.


Labronici PJ, Blunck SS, Lana FR, Esteves BB, Franco JS, Fukuyama JM, et al. Vitamin D and its relation to bone mineral density in postmenopause women. Rev Bras Ortop. 2013; 48(3):228-35.

PMid:31214537 PMCid:PMC6565868

Bhupathiraju SN, Alekel DL, Stewart JW, Hanson LN, Shedd KM, Reddy MB, et al. Relationship of circulating total homocysteine and C-reactive protein to trabecular bone in postmenopausal women. J Clin Densitom. 2007; 10(4):395-403.

PMid:17662632 PMCid:PMC2131712

Pasco JA, Kotowicz MA, Henry MJ, Nicholson GC, Spilsbury HJ, Box JD, et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA. 2006; 296(11):1349-55.


Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, et al. High-sensitivity C-reactive protein and risk of non traumatic fractures in the Bruneck study. Arch Intern Med. 2006; 166(22):2495-501.


Khashayar P, Meybodi HRA, Hemami MR, Keshtkar A, Dimai HP, Larijani B. Vitamin D status and its relationship with bone mineral density in a healthy Iranian population. Rev Bras Ortop. 2016; 51(4):454-8.

PMid:27517026 PMCid:PMC4974161

Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal

How to Cite
Safari, A., Borhani-Haghighi, A., Dianatpour, M., Heydari, S. T., Foroughinia, F., & Ranjbar Omrani, G. (2019). Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis. Galen Medical Journal, 8, e1548.
Original Article